article thumbnail

Optimizing Your Drug Patent Strategy: A Comprehensive Guide for Pharmaceutical Companies

Drug Patent Watch

Drug patents are a form of intellectual property protection that grants pharmaceutical companies exclusive rights to manufacture, sell, and profit from their innovations for a set period. This exclusivity is the lifeblood of the industry, allowing companies to recoup their substantial R&D investments and fund future discoveries.

article thumbnail

Understanding the Regulatory Environment in Japan for Generic Drug Development

Drug Patent Watch

This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. Pharmaceutical Regulations in Japan 2020. Regulatory System on Generic Drugs in Japan.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Advanced Solutions for Sustained Delivery of Ocular Therapies

PharmaTech

Pharmaceutical companies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. PLoS ONE 2011 6, e24513. DOI:10.1089/jop.2022.0144 2022.0144 Natarajan, J.V.; Johnson & Johnson Vision.

Dosage 64
article thumbnail

STAT+: As Trump pauses enforcement of an anti-bribery law, will pharma engage in bad behavior?

STAT

Between 2011 and 2020, 10 of the world’s largest pharmaceutical companies paid a combined $1.34 billion in fines to the U.S. government for bribing foreign officials in order to boost purchases of their medicines.

article thumbnail

Who is Dr. George Tidmarsh, the new director of CDER?

PharmaVoice

He was also CEO of La Jolla Pharmaceutical Company from 2011 to 2019, leading the development of a blood pressure drug that failed to meet sales expectations. His tenure there was defined by an approval for a rheumatoid arthritis drug Duexis that was later subject to pricing controversies.

article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. Having worked for CROs since graduating, Sophie joined Pfizer in 2011 and has had various roles within the UK and now global groups.

article thumbnail

Using RWE in rare disease drug development: effective innovations with historical controls

European Pharmaceutical Review

11 have recently conducted an analysis of international HTA submissions from 2011-2019 to determine the acceptability of single arm clinical studies and ECs as part of the drug reimbursement process. 2011 May; 46(3): 399–424. Patel et al. FDA presentation. Available at: [link]. Multivariate Behav Res. doi: 1080/00273171.2011.568786.